The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0314454 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PLOS ONE, 2025. Verfasst von Yongin Cho und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Inha University College of Medicine, Incheon, Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Atrial Fibrillation, Diabetic Cardiomyopathies, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Inha University.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Sodium glucose cotransporter 2 (SGLT2) inhibitors improve clinical outcomes in several populations including type 2 diabetes (T2D), chronic renal insufficiency, and heart failure (HF). However, limited data exist on their effects on atrial fibrillation (AF).
Methods
We conducted a retrospective cohort study using the National Health Insurance Service database. A total of 4,771 patients with T2D and AF who were newly prescribed SGLT2 inhibitors or DPP4 inhibitors were selected and matched in a 1:2 ratio by propensity score with 37 confounding variables. We assessed the effect of SGLT2 inhibitors on the composite outcome of either HF hospitalization or death.
Results
Over a median follow-up of 31 months, patients on SGLT2 inhibitors were associated with a lower risk of hospitalizations for HF or mortality compared to those on DPP4 inhibitors (HR 0.61; 95% CI 0.44–0.85; P = 0.004). SGLT2 inhibitor use was also associated with a lower risk of mortality (HR 0.61; 95% CI 0.39–0.94; P = 0.025) and CV mortality (HR 0.43; 95% CI 0.21–0.86; P = 0.018), but not of MI (HR 1.22 [95% CI 0.72–2.09]; P = 0.461) or stroke (HR 1.00 [95% CI 0.75–1.33]; P = 0.980). The incidence of hospitalizations for HF, although statistically insignificant, tended to be lower in the SGLT2 inhibitor group (HR 0.63 [95% CI 0.39–1.02]; P = 0.062).
Conclusion
In a nationwide cohort of patients with T2D and AF, SGLT2 inhibitor was associated with a lower risk of mortality, which may suggest that SGLT2 inhibitors may be considered as the first-line antidiabetic medication in patients with T2D and AF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Inha University College of Medicine, Incheon, Republic of Korea.
- Department of Cardiology, Inha University College of Medicine, Incheon, Republic of Korea.
- Department of Data Science, Hanmi Pharm Co., Ltd, Republic of Korea.
- Department of Biomedical Sciences, Inha University College of Medicine, Incheon, Korea.
ORCID-Profile: Sung-Hee Shin, Sojeong Park
Förderung
- Inha University
Zitieren
APA
Cho, Y., Shin, S. H., Park, M. A., Suh, Y. J., Park, S., Jang, J. H., Kim, D. Y., & Kim, S. H. (2025). The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation. PLOS ONE. https://doi.org/10.1371/journal.pone.0314454
Vancouver
Cho Y, Shin SH, Park MA, Suh YJ, Park S, Jang JH, et al. The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation. PLOS ONE. 2025. doi:10.1371/journal.pone.0314454
BibTeX
@article{Cho2025,
author = {Cho, Yongin and Shin, Sung-Hee and Park, Min-Ae and Suh, Young Ju and Park, Sojeong and Jang, Ji-Hun and Kim, Dae-Young and Kim, So Hun},
title = {The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0314454}
}
EUVIMED